AstraZeneca vs Qualcomm: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Qualcomm side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1985Qualcomm

   Qualcomm Founded

   Irwin Jacobs, Andrew Viterbi, and five colleagues found Qualcomm Incorporated in San Diego, California, initially operating as a telecommunications consulting and research firm from a converted restaurant building.

3. 1988Qualcomm

   OmniTRACS Commercial Launch

   Qualcomm commercially launches OmniTRACS, a satellite-based two-way messaging and positioning system for long-haul trucking that becomes the company's first profitable product and funds ongoing CDMA research.

4. 1989Qualcomm

   First Live CDMA Demonstration

   Qualcomm conducts its first outdoor live CDMA demonstration in San Diego, proving the technology works in real-world conditions and attracting serious attention from U.S. Cellular carriers and equipment manufacturers.

5. 1991Qualcomm

   Initial Public Offering

   Qualcomm goes public on the Nasdaq Stock Market in December 1991, raising approximately $43 million at $16 per share in an IPO that gives the company capital to accelerate CDMA commercialization.

6. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

7. 1993Qualcomm

   IS-95 CDMA Standard Adopted

   The Telecommunications Industry Association formally adopts IS-95, a CDMA standard based substantially on Qualcomm's technology, as an approved digital cellular standard in the United States validating the company's decade-long technological bet.

8. 1995Qualcomm

   First Commercial CDMA Network Launched

   Sprint PCS launches the first commercial CDMA cellular network in the United States, using Qualcomm-based technology and marking the beginning of large-scale commercial deployment that would define U.S. Wireless infrastructure for the next twenty years.

9. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

10. 1999Qualcomm

    Strategic Exit from Infrastructure and Handsets

    Qualcomm sells its network infrastructure division to Ericsson and its handset manufacturing business to Kyocera, focusing the company entirely on chip design and patent licensing a strategic concentration that defines its business model to the present day.

11. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

12. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

13. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

14. 2007Qualcomm

    Snapdragon Platform Introduction

    Qualcomm introduces the Snapdragon brand for its mobile system-on-chip processors, establishing a consumer-facing identity for its mobile silicon that would become synonymous with premium Android smartphone performance over the following decade.

15. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

16. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

17. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

18. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

19. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

20. 2019Qualcomm

    Apple Settlement and Licensing Agreement

    Following years of contentious litigation, Qualcomm and Apple reach a global settlement in April 2019 covering all pending litigation worldwide, with Apple agreeing to a multi-year chip supply deal and a licensing arrangement reportedly involving back payments…

21. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

22. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

23. 2021Qualcomm

    Nuvia Acquisition

    Qualcomm acquires Nuvia, a CPU startup founded by former Apple Silicon architects, for approximately $1.4 billion, bringing custom CPU design capabilities in-house that power the Oryon cores in Snapdragon 8 Elite and Snapdragon X Elite PC chips.

24. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

25. 2023Qualcomm

    Snapdragon X Elite PC Platform Launch

    Qualcomm launches the Snapdragon X Elite and Snapdragon X Plus platforms for Windows PCs, powering Microsoft's Copilot+ PC initiative and marking the company's most significant push into personal computing since the failed Snapdragon 835 PC effort in 2017.

26. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

27. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

28. 2024Qualcomm

    Snapdragon 8 Elite Launch

    Qualcomm launches the Snapdragon 8 Elite, its first phone chip with custom Oryon CPU cores, built on TSMC's 3nm process.

29. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

30. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

31. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

32. 2025Qualcomm

    Alphawave Semi Acquisition Completed

    Qualcomm completes its roughly $2.4B purchase of Alphawave Semi to accelerate data center connectivity products.

33. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

34. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

35. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

36. 2026Qualcomm

    Q2 FY2026 Results and $20B Buyback Authorization

    Qualcomm reports Q2 FY2026 revenue of $10.599B, record quarterly QCT automotive revenue, 20% year-over-year growth in combined QCT automotive and IoT revenue, and a new $20B repurchase authorization.

37. 2026Qualcomm

    Q3 FY2026 Results and $40B Non-Handset Target

    Qualcomm reports Q3 FY2026 revenue of $9.9B (down 4%), automotive revenue up 61% to $1.6B, and raises its FY2029 non-handset revenue target to $40B.

Acquisitions

Questions about AstraZeneca vs Qualcomm